# Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/ctad/123956) · 2026-11-18 · Medicine
Page: https://themorning.science/story/tau-therapy-shows-continued-benefit-at-2-years-in-alzheimer-s-257fae5b026d64b9
Kind: research · Impact: low

## In brief

- Diranersen, an investigational antisense oligonucleotide that targets tau, continued to show benefits for 96 weeks.
- The data come from the open-label extension of the phase II CELIA trial.
- The results were reported in meeting coverage from CTAD.

## Why it matters

It is early open-label extension data from a phase II trial, so it suggests a tau-targeting approach may be worth further study but does not establish efficacy. Science readers can use it to track whether tau-lowering therapies hold up in later, controlled trials.

## Coverage

- [Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's](https://www.medpagetoday.com/meetingcoverage/ctad/123956) — MedPageToday.com - medical news for physicians, 2026-11-18

Tags: alzheimers, tau, antisense oligonucleotide, clinical trial, neurodegeneration

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
